Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.66 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43996 | 1.00 | FOLH1 (0.66) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL9875634 | 1.00 | FOLH1 (0.66) | FOLH1GSRSLC6A5RNPEPCA1 | |
| Pyrrole SCHEMBL28847693 | 0.88 | FOLH1 (0.54) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL24141430 | 0.88 | FOLH1 (0.54) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL12572609 | 0.88 | FOLH1 (0.83) | FOLH1GSRSLC6A5RNPEPCPB2 | |
| SCHEMBL1006179 | 0.86 | FOLH1 (0.64) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL1006178 | 0.86 | FOLH1 (0.64) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL5497824 | 0.86 | FOLH1 (0.64) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL30109129 | 0.86 | FOLH1 (0.50) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL20530 | 0.84 | FOLH1 (0.62) | FOLH1GSRSLC6A5RNPEPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118056021-A | Method for determining target polymer in sample by using guide polymer | 牛津纳米孔科技公开有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-116376947-A | Method suitable for screening bacterial strain with high yield of non-protein amino acid | 北京理工大学 | 2023-07-04 | — | — | CN | claimed |
| US-9474292-B1 | Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals | EvoSci Biotech LLC (US) | 2016-10-25 | — | — | US | claimed |
| EP-1858352-B1 | A COMPOSITION COMPRISING A POWDER CONTAINING MICROENCAPSULATED POLYUNSATURATED LONG-CHAIN ESTERIFIED FATTY ACIDS DISTRIBUTED IN AN EFFERVESCENT BASE | DELANTE HEALTH AS (NO) | 2013-06-05 | — | — | EP | claimed |
| US-20080279935-A1 | Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base | SWG INVEST AS (NO) | 2008-11-13 | — | — | US | claimed |
| EP-1858352-A1 | A COMPOSITION COMPRISING A POWDER CONTAINING MICROENCAPSULATED POLYUNSATURATED LONG-CHAIN ESTERIFIED FATTY ACIDS DISTRIBUTED IN AN EFFERVESCENT BASE | Core Competence Sweden AB (SE) | 2007-11-28 | — | — | EP | claimed |
| WO-2006088418-A1 | A COMPOSITION COMPRISING A POWDER CONTAINING MICROENCAPSULATED POLYUNSATURATED LONG-CHAIN ESTERIFIED FATTY ACIDS DISTRIBUTED IN AN EFFERVESCENT BASE | CORE COMPETENCE SWEDEN AB (SE) | 2006-08-24 | — | — | WO | claimed |
| US-6811793-B2 | TABLET THAT INCLUDES STEVIA, WATER SOLUBLE BINDER, WATER SOLUBLE LUBRICANT, ACTIVE AGENT, AND EFFERVESCENT AGENT. | AMERILAB TECHNOLOGIES, INC. | 2004-11-02 | — | — | US | claimed |
| US-20030170301-A1 | Effervescent composition including stevia | AMERILAB TECHNOLOGIES, INC. | 2003-09-11 | — | — | US | claimed |
| EP-3445343-B1 | COMPOSITION AND METHOD FOR PRETREATING CANCER | VALCURIA AB (SE) | 2026-02-25 | — | — | EP | disclosed |
| EP-4114865-B1 | PROTEASE-PROCESSED MOLECULES | SANOFI SA (FR) | 2026-01-28 | — | — | EP | disclosed |
| US-20250302915-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE DAMAGE AND ARTHRITIS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-20250171512-A1 | FGF21 VARIANTS | SANOFI SA (FR) | 2025-05-29 | — | — | US | disclosed |
| CN-119421888-A | Mammalian milk-derived peptides having antimicrobial activity | 马楚比尔斯公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-0693926-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF A STABLE POWDER CONTAINING AN ACTIVE PRINCIPLE COMPRISING AN ASSOCIATION OF ACETYLSALICYLIC ACID AND METOCLOPRAMIDE | UNION PHARMA SCIENT APPL (FR) | 1996-01-31 | — | — | EP | disclosed |
| US-5480652-A | HAVING IMPROVED STABILITY | LABORATOIRES UPSA (FR) | 1996-01-02 | — | — | US | disclosed |
| EP-0673245-A1 | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN AND METHOD FOR PREPARING SAME. | UNION PHARMA SCIENT APPL (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-5437874-A | Water soluble salt or complex of acetylsalicylic acid with metoclopramide or salt, stabilized with hydrophilic polymer | LABORATOIRES UPSA (FR) | 1995-08-01 | — | — | US | disclosed |
| WO-1995014462-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF A STABLE POWDER CONTAINING AN ACTIVE PRINCIPLE COMPRISING AN ASSOCIATION OF ACETYLSALICYLIC ACID AND METOCLOPRAMIDE | LABORATOIRES UPSA (FR) | 1995-06-01 | — | — | WO | disclosed |
| WO-1994013279-A1 | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN AND METHOD FOR PREPARING SAME | LABORATOIRES UPSA (FR) | 1994-06-23 | — | — | WO | disclosed |